Overview

• Oncology firm's Q4 net loss narrowed to $30.5 mln from $36.3 mln last year

• Company raised $264 mln, extending cash runway into 2H 2028

• Significant clinical advancements in rinzimetostat and enozertinib reported

Outlook

• ORIC expects rinzimetostat dose optimization data in Q1 2026

• Company plans to initiate Phase 3 trial for rinzimetostat in 1H 2026

• ORIC anticipates enozertinib monotherapy data in 2H 2026

Result Drivers

• R&D EXPENSES - Reduced to $25.9 mln from $32 mln due to lower rinzimetostat drug manufacturing costs and lower costs from discontinued programs

• CASH RUNWAY EXTENSION - Company raised $264 mln, extending cash runway into 2H 2028

Company press release: ID:nGNX4wfBSH

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Net Income		-$30.51 mln
Q4 Income from Operations		-$34.55 mln
Q4 Operating Expenses		$34.55 mln

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the biotechnology & medical research peer group is "buy"

• Wall Street's median 12-month price target for Oric Pharmaceuticals Inc is $22.00, about 98% above its February 20 closing price of $11.11

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.